Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Noninvasive Transdermal Delivery System of Lidocaine Using an Acoustic Droplet‐Vaporization Based Wearable Patch
Small ( IF 13.0 ) Pub Date : 2018-10-17 , DOI: 10.1002/smll.201803266 Fernando Soto 1 , Itthipon Jeerapan 1 , Cristian Silva-López 1 , Miguel Angel Lopez-Ramirez 1 , Ingrid Chai 1 , Lu Xiaolong 2 , Jian Lv 1 , Jonas F. Kurniawan 1 , Ian Martin 1 , Krishnan Chakravarthy 1, 3 , Joseph Wang 1
Small ( IF 13.0 ) Pub Date : 2018-10-17 , DOI: 10.1002/smll.201803266 Fernando Soto 1 , Itthipon Jeerapan 1 , Cristian Silva-López 1 , Miguel Angel Lopez-Ramirez 1 , Ingrid Chai 1 , Lu Xiaolong 2 , Jian Lv 1 , Jonas F. Kurniawan 1 , Ian Martin 1 , Krishnan Chakravarthy 1, 3 , Joseph Wang 1
Affiliation
|
Current technologies for managing acute and chronic pain have focused on reducing the time required for achieving high therapeutic efficiency. Herein a wearable transdermal patch is introduced, employing an acoustic droplet vaporization (ADV) methodology, as an effective noninvasive transdermal platform, for a fast local delivery of the anesthetic agent lidocaine. The skin‐worn patch consists of a flexible drug reservoir containing hundreds of micropores loaded with lidocaine, and mixed with the perfluorocarbon (PFC) emulsion. The ultrasound‐triggered vaporization of the PFC emulsion provides the necessary force to breach dermal barriers. The drug release kinetics of our model was investigated by measuring the amount of lidocaine that passed through phantom tissue and pigskin barriers. The ADV platform increases the payload skin penetration resulting in shorter treatment times compared to passive diffusion or ultrasound alone, holding considerable promise for addressing the delayed therapeutic action and slow pain relief of existing delivery protocols. It is envisioned that the integration of ADV‐based transdermal devices could be expanded to the depth‐dependent delivery of other pain management, vaccines, and gene therapy modalities.
中文翻译：
利多卡因的无创透皮给药系统，使用基于声波液滴蒸发的可穿戴贴片
当前用于管理急性和慢性疼痛的技术已集中在减少实现高治疗效率所需的时间上。在本文中，引入可穿戴的透皮贴剂，采用声滴汽化（ADV）方法作为有效的非侵入性透皮平台，以快速局部递送麻醉剂利多卡因。皮肤破损贴剂由一个柔性药物储库组成，该储库包含数百个装载利多卡因的微孔，并与全氟化碳（PFC）乳液混合。超声触发的PFC乳化液汽化提供了突破真皮屏障的必要作用力。通过测量通过体模组织和猪皮屏障的利多卡因的量，研究了我们模型的药物释放动力学。与单独的被动扩散或超声相比，ADV平台增加了有效载荷皮肤的穿透力，从而缩短了治疗时间，为解决现有治疗方案的延迟治疗作用和缓慢疼痛缓解提供了广阔前景。可以预见，基于ADV的透皮设备的集成可以扩展到其他疼痛管理，疫苗和基因治疗方式的深度依赖交付。
更新日期：2018-10-17
中文翻译：
利多卡因的无创透皮给药系统，使用基于声波液滴蒸发的可穿戴贴片
当前用于管理急性和慢性疼痛的技术已集中在减少实现高治疗效率所需的时间上。在本文中，引入可穿戴的透皮贴剂，采用声滴汽化（ADV）方法作为有效的非侵入性透皮平台，以快速局部递送麻醉剂利多卡因。皮肤破损贴剂由一个柔性药物储库组成，该储库包含数百个装载利多卡因的微孔，并与全氟化碳（PFC）乳液混合。超声触发的PFC乳化液汽化提供了突破真皮屏障的必要作用力。通过测量通过体模组织和猪皮屏障的利多卡因的量，研究了我们模型的药物释放动力学。与单独的被动扩散或超声相比，ADV平台增加了有效载荷皮肤的穿透力，从而缩短了治疗时间，为解决现有治疗方案的延迟治疗作用和缓慢疼痛缓解提供了广阔前景。可以预见，基于ADV的透皮设备的集成可以扩展到其他疼痛管理，疫苗和基因治疗方式的深度依赖交付。
京公网安备 11010802027423号